202 related articles for article (PubMed ID: 11735606)
1. Quantitative pharmacogenetics of nortriptyline: a novel approach.
Kvist EE; Al-Shurbaji A; Dahl ML; Nordin C; Alván G; Ståhle L
Clin Pharmacokinet; 2001; 40(11):869-77. PubMed ID: 11735606
[TBL] [Abstract][Full Text] [Related]
2. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.
Dahl ML; Bertilsson L; Nordin C
Psychopharmacology (Berl); 1996 Feb; 123(4):315-9. PubMed ID: 8867869
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
5. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
Lee SY; Ki CS; Hong KS; Kim JW
J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1998 Oct; 64(4):384-90. PubMed ID: 9797795
[TBL] [Abstract][Full Text] [Related]
7. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
8. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.
Jornil J; Jensen KG; Larsen F; Linnet K
Eur J Pharm Sci; 2011 Oct; 44(3):265-72. PubMed ID: 21854846
[TBL] [Abstract][Full Text] [Related]
10. Sequence-based CYP2D6 genotyping in the Korean population.
Lee SY; Sohn KM; Ryu JY; Yoon YR; Shin JG; Kim JW
Ther Drug Monit; 2006 Jun; 28(3):382-7. PubMed ID: 16778723
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between nortriptyline and terbinafine.
Van Der Kuy PH; Van Den Heuvel HA; Kempen RW; Vanmolkot LM
Ann Pharmacother; 2002 Nov; 36(11):1712-4. PubMed ID: 12398564
[TBL] [Abstract][Full Text] [Related]
12. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression.
Murphy GM; Pollock BG; Kirshner MA; Pascoe N; Cheuk W; Mulsant BH; Reynolds CF
Neuropsychopharmacology; 2001 Nov; 25(5):737-43. PubMed ID: 11682257
[TBL] [Abstract][Full Text] [Related]
14. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.
Jerling M; Merlé Y; Mentré F; Mallet A
Br J Clin Pharmacol; 1994 Nov; 38(5):453-62. PubMed ID: 7893588
[TBL] [Abstract][Full Text] [Related]
17. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Dalén P; Dahl ML; Bernal Ruiz ML; Nordin J; Bertilsson L
Clin Pharmacol Ther; 1998 Apr; 63(4):444-52. PubMed ID: 9585799
[TBL] [Abstract][Full Text] [Related]
18. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
Kirchheiner J; Sasse J; Meineke I; Roots I; Brockmöller J
Pharmacogenetics; 2003 Dec; 13(12):721-8. PubMed ID: 14646691
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of mirtazapine.
Grasmäder K; Verwohlt PL; Kühn KU; Dragicevic A; von Widdern O; Zobel A; Hiemke C; Rietschel M; Maier W; Jaehde U; Rao ML
Eur J Clin Pharmacol; 2004 Sep; 60(7):473-80. PubMed ID: 15289959
[TBL] [Abstract][Full Text] [Related]
20. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]